Dr. Catherine Nyongesa Hails Major Breast Cancer Breakthrough as “New Dawn” for Patients
0
0
By John Kariuki
Dr. Catherine Nyongesa, leading oncologist at Texas Cancer Center, has welcomed a major breakthrough in breast cancer treatment, calling it “a new dawn” for patients with HER2-positive metastatic breast cancer.
The optimism follows new research presented at the American Society for Clinical Oncology (ASCO) conference, showing that a novel therapy cuts the risk of disease progression or death by nearly half. It’s the most significant advancement in treating this aggressive subtype in over a decade.
“This is fantastic news for our patients,” said Dr. Nyongesa. “For years, we’ve had limited tools to manage HER2-positive metastatic breast cancer. This breakthrough brings real hope.”
HER2-positive breast cancer, accounting for 15–20% of cases, is driven by an overactive gene that fuels rapid cancer growth. It’s known for being aggressive and difficult to treat—especially in later stages.
Dr. Nyongesa emphasized the importance of having new first-line therapy options:
“This could dramatically improve both survival rates and quality of life, especially for those diagnosed at an advanced stage.”
The promising treatment is expected to be submitted for regulatory approval soon, raising hopes for fast-track access in cancer clinics globally.
Dr. Nyongesa urged continued investment in oncology research: “Breakthroughs like this don’t happen by accident—they come from years of science, sacrifice, and persistence. Every step forward gives our patients a better shot at life.”
As Kenya and the world continue the fight against cancer, this milestone is being hailed by clinicians as a major leap toward more effective and personalized treatment.
About The Author
